Israel’s CytoReason (see here previously) is partnering Swiss multinational Ferring to find new treatments for patients with inflammatory bowel disease (IBD). CytoReason’s AI technology will enable the joint building of models of diseased cells on which therapies will be tested.

https://www.timesofisrael.com/swiss-pharma-firm-ferring-israels-cytoreason-join-to-battle-bowel-disease/